As of Friday close, Avalo Therapeutics Inc.’s (NASDAQ:AVTX) stock was down -$0.03, moving down -11.53 percent to $0.17. The average number of shares traded per day over the past five days has been 2,241,360 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0145 fall in that time frame. In the last twenty days, the average volume was 1,506,320, while in the previous 50 days, it was 1,961,420.
Since last month, AVTX stock retreated -50.54%. Shares of the company fell to $0.1750 on 08/04/23, the lowest level in the past month. A 52-week high of $7.13 was reached on 01/18/23 after having rallying from a 52-week low of $0.17. Since the beginning of this year, AVTX’s stock price has dropped by -96.53% or -$4.8651, and marked a new high 4 times. However, the stock has declined by -97.55% since its 52-week high.
AVTX stock investors should be aware that Avalo Therapeutics Inc. (AVTX) stock had its last reported insider trading activity 39 days ago on Jun 27. ARMISTICE CAPITAL, LLC, the 10% Owner of the company, disposed of 937,404 shares for $0.52 on Jun 27. It resulted in a $486,888 divestment by the insider. ARMISTICE CAPITAL, LLC sold 2,746,138 shares at an average price of $0.61 on Jun 26. The insider now owns 1,668,862 shares following the transaction. On Jun 20, 10% Owner Caissa Capital Management ltd. bought 2,000 shares at $4.14 apiece. The transaction was valued at $8,289.
Financial Health
In the three months ended June 29, Avalo Therapeutics Inc.’s quick ratio stood at 0.80, while its current ratio was 0.80, showing that the company is not able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 81.20% percent. Based on annual data, AVTX earned $14.62 million in gross profit and brought in $18.05 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -440.80%. Return on equity (ROE) for the past 12 months was 470.00%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. AVTX’s revenue fell -60.94% to $0.48 million during the quarter, while net income inched up to $0.64 million. While analysts expected Avalo Therapeutics Inc. to report -$0.8 quarterly earnings, the actual figure was -$0.59 per share, beating the consensus estimate by 26.30%. During the quarter, the company generated -$6.76 million in EBITDA. The liabilities of Avalo Therapeutics Inc. were 31.2 million at the end of its most recent quarter ended June 29, and its total debt was $14.12 million. The value of shareholders’ equity is $20.25 million.
Technical Picture
This quick technical analysis looks at Avalo Therapeutics Inc.’s (AVTX) price momentum. With a historical volatility rate of 97.22%, the RSI 9-day stood at 20.18% on 04 August.
With respect to its five-day moving average, the current Avalo Therapeutics Inc. price is down by -7.65% percent or -$0.0145. At present, AVTX shares trade -50.98% below its 20-day simple moving average and -92.68% percent below its 100-day simple moving average. However, the stock is currently trading approximately -94.22% below its SMA50 and -96.73% below its SMA200.
Stochastic coefficient K was 12.68% and Stochastic coefficient D was 12.81%, while ATR was 0.0586. Given the Stochastic reading of 0.00% for the 14-day period, the RSI (14) reading has been calculated as 26.33%. As of today, the MACD Oscillator reading stands at -0.0113, while the 14-day reading stands at -0.0472.
Analyst Ratings
RBC Capital Mkts launched its rating on Avalo Therapeutics Inc. (NASDAQ: AVTX) to an Outperform in a note to investors on September 24, 2021. Avalo Therapeutics Inc. (AVTX) has been rated Hold by analysts. According to 0 brokerage firms, AVTX is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Avalo Therapeutics Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $0.75, the current consensus forecast for the stock is $0.75 – $0.75. Based on these forecasts, analysts predict Avalo Therapeutics Inc. (AVTX) will achieve an average price target of $0.75.
